Oruka Therapeutics, Inc. Share Price

Oruka Therapeutics, Inc. Share Price

NASDAQ: ORKA | Mid Cap
$96.84
+$0.37 (0.38%) Last updated on 31 Oct, 2026 | 01:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Oruka Therapeutics, Inc. Stock Performance

Open
$95.97
Prev. Close
$96.47
Circuit Range
N/A
Day Range
$94.87 - $97.53
Year Range
$25.32 - $115.52
Volume
39,718
Average Traded
$95.57

Oruka Therapeutics, Inc. Share Price Today

As of 31 October 2026, Oruka Therapeutics, Inc.'s share price is $96.84. The stock opened at $95.97, compared to its previous close of $96.47. During today's trading session, Oruka Therapeutics, Inc.'s share price traded between $94.87 and $97.53, with an average price of $96.20. Over the past 52 weeks, the stock has recorded a high of $115.52 and a low of $25.32. In terms of performance, Oruka Therapeutics, Inc.'s share price has risen by 41.11% over the last six months and is up 244.03% on a year-on-year basis.

Oruka Therapeutics, Inc. Share Price Chart

Line chart of the Oruka Therapeutics, Inc. price trend over the selected period. The price rose overall, ranging from 94.82 to 97.53, ending at 96.92.
$94.87$97.53
L
Show Current Price
H

Oruka Therapeutics, Inc. Stock Fundamentals & Key Indicators

Market Cap
$4.42B
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-1.74
Revenue (TTM)
$0.00
Return On Equity (TTM)
-10.34%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-45.05%

Oruka Therapeutics, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$24.04-$24.50-$31.82-$34.87
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-1.91%-29.88%-9.59%

Oruka Therapeutics, Inc. Annual Profit & Loss

All figures in USD

Particulars2025
Revenue$0.00
Net Profit-$84.31
Net Profit MarginN/A
Income ChangeN/A

About Oruka Therapeutics, Inc.

Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.

Oruka Therapeutics, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$82.85
$96.82
+16.27%
Sep 2026
$91.37
$83.27
-13.63%
Aug 2026
$94.78
$96.41
-0.15%
Jul 2026
$94.76
$96.55
+1.44%
Jun 2026
$57.42
$95.17
+62.75%
May 2026
$68.50
$58.48
-14.79%
Apr 2026
$49.50
$68.63
+39.83%
Mar 2026
$33.70
$49.08
+42.63%
Feb 2026
$34.65
$34.41
+0.56%
Jan 2026
$30.35
$34.22
+12.77%
Dec 2025
$28.90
$30.34
+0.58%
Nov 2025
$27.39
$30.17
+7.18%

ORKA Share Price FAQs